<DOC>
	<DOCNO>NCT02433457</DOCNO>
	<brief_summary>To evaluate PK profile newly develop CC-292 SDD formulation compare CC-292 P22 tablet .</brief_summary>
	<brief_title>Relative Bioavailability Study CC-292</brief_title>
	<detailed_description>This single center , open-label , randomize , seven-treatment , seven-period , crossover design . The study consist screen phase , treatment phase , follow-up phone call . Approximately 24 healthy adult subject ( male female ) enrol .</detailed_description>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>1 . Must understand voluntarily sign write Informed Consent Form ( ICF ) prior studyrelated assessments/procedures conduct . 2 . Must able communicate Investigator , understand , comply requirement study , agree adhere restriction examination schedule . 3 . Must male female subject race 18 65 year age ( inclusive ) time sign ICF , good health determine Physical Examinations ( PE ) . 4 . Must comply follow acceptable form contraception : 1 . Male subject ( include vasectomy ) engage activity conception possible must use barrier contraception male condom NOT make natural animal membrane ( e.g. , latex polyurethane condom acceptable ) study drug , least 90 day last dose study drug . 2 . Females childbearing potential ( FCBP ) 1 must negative pregnancy test Screening Baseline ( i.e. , Day 1 ) . FCBP engage activity conception possible must agree use one follow form contraception entire participation study least 30 day administration last dose study drug : Option 1 : Any one following : nonoral hormonal contraception ( e.g. , injection , implant , transdermal patch , vaginal ring ) ; intrauterine device ; tubal ligation ; partner vasectomy ; OR Option 2 : Oral contraceptive pill PLUS one additional barrier method following : ( ) male female condom NOT make natural animal membrane ( e.g. , latex polyurethane acceptable ) ; ( b ) diaphragm spermicide ; ( c ) cervical cap spermicide ; ( ) contraceptive sponge spermicide ; OR Option 3 : TWO follow barrier method : ( ) male female condom NOT make natural animal membrane ( e.g. , latex polyurethane acceptable ) ; ( b ) diaphragm spermicide ; ( c ) cervical cap spermicide ; ( ) contraceptive sponge spermicide . Note : All female must surgically sterilize least 6 month Screening ( proper documentation require ) , postmenopausal ( defined 24 month without menses Screening , estradiol level &lt; 30 pg/mL plasma Follicle Stimulating Hormone ( FSH ) level &gt; 40 IU/L Screening ) . 5 . Must Body Mass Index ( BMI ) 18 33 kg/m2 ( inclusive ) . 6 . No clinically significant laboratory test result , determine Investigator . 7 . Must afebrile , supine systolic BP 90 140 mmHg , supine diastolic Blood Pressure ( BP ) 60 90 mmHg , pulse rate 40 110 bpm . 8 . Must normal clinically acceptable 12lead Electrocardiogram ( ECG ) Screening . Male subject must QTcF value ≤ 430 msec . Female subject must QTcF value ≤ 450 msec . 1 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . 2 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study , confound ability interpret data study . 3 . Use prescribed systemic topical medication ( include limit antibiotic , analgesic , anesthetic , etc . ) prior 30 day first dose administration , unless Sponsor agreement obtain . 4 . Use nonprescribed systemic topical medication ( include vitamin/mineral supplement , herbal medicine ) within 7 day first dose administration , unless Sponsor agreement obtain . 5 . Any surgical medical condition possibly affect drug absorption , distribution , metabolism excretion ( e.g. , bariatric procedure ) , plan elective medical procedure conduct trial . Subjects post cholecystectomy post appendectomy may include . 6 . Exposure investigational drug within 30 day prior first dose administration 5 halflives investigational drug , know ( whichever longer ) . 7 . Donated blood plasma prior 4 week first dose administration blood bank blood donation center . 8 . History multiple drug allergy ( i.e. , two ) ; 9 . History drug abuse ( define current version Diagnostic Statistical Manual [ DSM ] ) prior 2 year first dose administration , positive drug screen reflect consumption illicit drug . 10 . History alcohol abuse ( define current version DSM ) prior 2 year dose , positive alcohol screen . 11 . Known hepatitis , know carrier Hepatitis B Surface Antigen ( HBsAg ) , Hepatitis C Virus Antibody ( HCVAb ) , positive result test HBsAg , HCVAb , Human Immunodeficiency Virus ( HIV ) antibodies Screening . 12 . History smoking use nicotine containing product prior 3 month Screening self reporting . 13 . Female subject lactate breastfeed child .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>CC-292</keyword>
	<keyword>Open-Label</keyword>
	<keyword>Bioavailability Pharmacokinetics</keyword>
	<keyword>Phase I</keyword>
</DOC>